erenumab

all catalysts(0)

nothing on the calendar yet

News(4)

• New guidelines on migraine prevention reflect increasing options for patients
  “There has been a wealth of new treatment available” for migraine prevention, said a co-author of new guidelines released Monday.
  stat · 1mo ago
• Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials
  Slate Medicines is hurtling toward a Nasdaq listing, securing a reverse merger with Fulcrum Therapeutics six months after exiting stealth and ahead of the publication of clinical data on its lead c…
  fiercebiotech · 1mo ago
• A new Westlake-backed biotech takes aim at migraines
  Vedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention.
  biopharma_dive · 3mo ago
• Study data convince Lundbeck to push new migraine drug forward
  A possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.
  biopharma_dive · 4mo ago